Inspire Medical Systems reported a modest 1.6% revenue growth in Q1 and lowered its 2026 guidance by up to 10%, citing increased competition from GLP-1 drugs and rival devices, reimbursement challenges, and coding issues with its new Inspire 5 system. The company is also facing operational headwinds as it contracts territories and shifts focus to supporting existing accounts rather than expanding aggressively. Despite a 20% drop in its stock price, the current valuation still assumes optimistic growth and margin improvements that are not supported by recent results. The analyst maintains a Sell rating on the stock due to these challenges and uncertainties.
Terra Innovatum Global filed its 2025 Annual Report on Form 10-K, marking its first full year as a public company. The company ended fiscal 2025 with $102.9 million in cash and no debt, supported by proceeds from its business combination with GSR III...
ARC Resources Ltd. announced a quarterly eligible dividend of $0.21 per share payable on July 15, 2026, to shareholders recorded by June 30, 2026. The company, a major Montney producer in Canada, has paid a total of $0.80 per share over the past 12 m...
The Lovesac Company has named Andrew Farag as its new Executive Vice President, Chief Financial Officer, and Treasurer, effective immediately. Farag brings over 20 years of experience in finance and operations, having held CFO and COO roles in variou...
SpaceX (SPCX) went public on June 12, opening at $150 and closing its first day at $161, a 19% gain from the $135 IPO price. The stock's near-term price action is driven by retail excitement and the Starship launch narrative, but key price catalysts ...
Mondelēz International announced that Amit Banati will become its Executive Vice President and Chief Financial Officer effective July 1, 2026. Banati brings extensive financial and commercial experience from previous roles at Kenvue, Kellanova, Kello...
